| Recruiting | Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies AML (Acute Myeloid Leukemia), Glioma, Cholangiocarcinoma | Phase 4 | 2026-02-23 |
| Recruiting | Study of Olutasidenib and Temozolomide in HGG High Grade Glioma, Astrocytoma, Astrocytoma, Grade III | Phase 2 | 2025-03-01 |
| Recruiting | Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) Low Risk Myelodysplastic Syndromes | Phase 1 / Phase 2 | 2022-09-12 |
| Terminated | Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP ITP, Immune Thrombocytopenia | — | 2021-05-18 |
| Completed | Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety o Covid19, SARS (Severe Acute Respiratory Syndrome), SARS Pneumonia | Phase 3 | 2021-03-25 |
| Enrolling By Invitation | A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hem Warm Antibody Autoimmune Hemolytic Anemia | Phase 3 | 2019-10-30 |
| Completed | A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the T Warm Antibody Autoimmune Hemolytic Anemia | Phase 3 | 2019-04-24 |
| Completed | A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA) Warm Antibody Autoimmune Hemolytic Anemia | Phase 2 | 2016-07-01 |
| Withdrawn | Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy IGA Nephropathy | Phase 2 | 2015-09-01 |
| Completed | A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Pur Immune Thrombocytopenic Purpura | Phase 3 | 2015-01-01 |
| Completed | Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) Immune Thrombocytopenic Purpura | Phase 3 | 2014-10-01 |
| Completed | Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy IGA Nephropathy | Phase 2 | 2014-10-01 |
| Completed | A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura Immune Thrombocytopenic Purpura | Phase 3 | 2014-07-14 |
| Completed | Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients( Chronic Graft-versus-host Disease | Phase 2 | 2014-03-01 |
| Completed | To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca Keratoconjunctivitis Sicca | Phase 2 | 2013-07-01 |
| Completed | A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease Keratoconjunctivitis Sicca | Phase 1 | 2012-11-01 |
| Completed | Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Eryt Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic | Phase 2 | 2012-08-01 |
| Completed | A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma Asthma | Phase 2 | 2012-07-01 |
| Completed | Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma T Cell Lymphoma | Phase 2 | 2009-03-01 |
| Withdrawn | Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus Systemic Lupus Erythematosus | Phase 2 | 2008-11-01 |
| Completed | Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis Rheumatoid Arthritis | Phase 2 | 2008-05-01 |
| Completed | Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3) Rheumatoid Arthritis | Phase 2 | 2008-05-01 |
| Completed | Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma Lymphoma | Phase 1 / Phase 2 | 2007-04-01 |
| Completed | Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Pur Purpura, Thrombocytopenic, Idiopathic | Phase 2 | 2007-01-01 |
| Completed | Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1) Rheumatoid Arthritis | Phase 2 | 2006-08-01 |
| Completed | 7 Day Study of Mast Cell Inhibitor, R926112, in Patients With Symptomatic Seasonal Allergic Rhinitis Rhinitis, Allergic, Seasonal | Phase 2 | 2005-07-01 |
| No Longer Available | Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP Immune Thrombocytopenic Purpura | — | — |